Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1

Leukemia and Lymphoma

Volumn 53, Issue 8, 2012, Pages 1586-1591

  Kim, Joo Hyun ^a   Kim, Won Seog ^a   Park, Chaehwa ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

B cell lymphoma; LMP1; rituximab resistance

Indexed keywords

CD20 ANTIGEN; LATENT MEMBRANE PROTEIN 1; MICRORNA 155; PROTEIN KINASE B; PROTEIN MCL 1; RITUXIMAB;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, B-CELL; MICRORNAS; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS C-BCL-2; VIRAL MATRIX PROTEINS;

EID: 84864240470     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.659736     Document Type: Article

References (24)

1. W eiss LM, Movahed LA, Warnke RA, et al. Detection of Epstein- Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 1989;320:502-506.
2. K won JM, Park YH, Kang JH, et al. Th e eff ect of Epstein-Barr virus status on clinical outcome in Hodgkin's lymphoma. Ann Hematol 2006;85:463-468.
3. F ahraeus R, Fu HL, Ernberg I, et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988;42:329-338.
4. S hibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 1992;140:769-774.
5. M urray PG, Young LS, Rowe M, et al. Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffi n sections of Hodgkin's disease. J Pathol 1992;166:1-5.
6. Peng M, Lundgren E. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 1992;7:1775-1782.
7. Gires O, Zimber-Strobl U, Gonnella R, et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J 1997;16:6131-6140.
8. H uen DS, Henderson SA, Croom-Carter D, et al. Th e Epstein- Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two eff ector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995;10:549-560.
9. Mcfarland EDC, Izumi KM, Mosialos G. Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NFkB. Oncogene 1999;19:6959-6964.
10. Park S, Lee J, Ko YH, et al. Th e impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007;110:972-978.
11. K im JH, Kim WS, Park C, et al. Egr-1, a new downstream molecule of Epstein-Barr virus latent membrane protein 1. FEBS Lett 2007;581:623-628.
12. K im JH, Kim WS, Park C. SNARK, a novel downstream molecule of EBV latent membrane protein 1, is associated with resistance to cancer cell death. Leuk Lymphoma 2008;49:1392-1398.
13. B onavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007;26:3629-3636.
14. S tolz C, Hess G, Hähnel PS, et al. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood 2008;112:3312-3321.
15. Suzuki E, Umezawa K, Bonavida B. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene 2007;26:6184-6193.
16. Jazirehi AR, Vega MI, Bonavida B. Development of rituximabresistant lymphoma clones with altered cell signaling and crossresistance to chemotherapy. Cancer Res 2007;67:1270-1281.
17. Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, et al. Acquired resistance to rituxiamb resulting from decreased Bax and Bak expression. Clin Cancer Res 2008;14:1550-1560.
18. Pavan A, Spina M, Canzonieri V, et al. Recent prognostic factors in duff use large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies. Leuk Lymphoma 2008;49:2048-2058.
19. Tao YG, Tan YN, Liu YP, et al. Epstein-Barr virus latent membrane protein 1 modulates epidermal growth factor receptor promoter activity in a nuclear factor kappa B-dependent manner. Cell Signal 2004;16:781-790.
20. Yamanaka Y, Tagawa H, Takahashi N, et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood 2009;114:3265-3275.
21. Kluiver J, Haralambieva E, de Jong D, et al. Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma. Genes Chromosomes Cancer 2006;45:147-153.
22. K luiver J, Poppema S, de Jong D, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 2005;207:243-249.
23. I nomata M, Tagawa H, Guo YM, et al. MicroRNA-17 - 92 downregulates expression of distinct targets in diff erent B-cell lymphoma subtypes. Blood 2007;113:396-402.
24. L innstaedt SD, Gottwein E, Skalsky RL, et al. Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol 2010;84:11670-11678.